{
    "elements": [
        {
            "type": "table",
            "sequence_num": 1,
            "data": {
                "num_rows": 15,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "RESEARCH & DEVELOPMENT AMENDMENTS"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "MEHTSOP059"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP)"
                    },
                    {
                        "text": "SOP"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "All staff"
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "th12 December 2019"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "th11 December 2022"
                    },
                    {
                        "text": "Developed in response to:"
                    },
                    {
                        "text": "Service Development"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "17"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "Research & Development"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Lauren Perkins, R & D Manager"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box/es to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "\uf0fcMEHT \u25a1 BTUH \u25a1 SUH"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "Research and Development"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "04/07/2019"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Tracey Camburn R & D Director Clinical Lead Nurse"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "26/07/2019"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "DRAG Chair's Action"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "12th December 2019"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from Document Ratification Group"
                    },
                    {
                        "text": "Date: December 2019"
                    },
                    {
                        "text": "Distribution Method:"
                    },
                    {
                        "text": "Intranet & Website"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 2,
            "data": {
                "url": "MEHTSOP059 Amendments 1.0.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 3,
            "data": {
                "num_rows": 13,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Consulted With:"
                    },
                    {
                        "text": "Post/ Approval Committee/ Group:"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Mandy Austin"
                    },
                    {
                        "text": "R & D Coordinator"
                    },
                    {
                        "text": "01/07/2019 04/07/2019"
                    },
                    {
                        "text": "Jenny Child"
                    },
                    {
                        "text": "Research Assistant"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 1,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 10,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ Record documents superseded by:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Lauren Perkins"
                    },
                    {
                        "text": "Newly created"
                    },
                    {
                        "text": "12th December 2019"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 6,
            "data": {
                "is_heading": 1,
                "text": "Contents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 7,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Background"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 8,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Purpose"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 9,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Applicable"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 10,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Responsibilities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 11,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Procedure"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 12,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Related documents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 13,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "References"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 14,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Equality Impact Assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 15,
            "data": {
                "is_heading": 0,
                "text": "Appendix 1 - Definitions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 16,
            "data": {
                "is_heading": 0,
                "text": "Appendix 2 - Flowchart of Amendment Process"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 17,
            "data": {
                "is_heading": 0,
                "text": "Appendix 3 - Examples of Substantial and Non-Substantial Amendments Appendix 4 - Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 18,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "BACKGROUND"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 19,
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "This document sets out the procedures to be followed by all Mid Essex Hospital Services NHS Trust (MEHT) staff who are responsible for submitting and implementing amendments for research studies run at MEHT."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 20,
            "data": {
                "is_heading": 0,
                "prefix": 1.2,
                "text": "It provides clear guidance on the procedure of classifying and seeking approval for amendments."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 21,
            "data": {
                "is_heading": 1,
                "text": "Notification of amendments"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 22,
            "data": {
                "is_heading": 0,
                "prefix": 1.3,
                "text": "If MEHT is the Sponsor ensure that all amendments to clinical trial documentation are submitted to the R&D Office for approval as well as the applicable Research Ethics  Committee  (REC),  Health  Research  Authority  and/or  the  Medicines  and Healthcare Products Regulatory Agency (MHRA) prior to implementation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 23,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "PURPOSE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 24,
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "This SOP describes the process for submitting and implementing both substantial and non-substantial amendments for MEHT sponsored studies. Principles in this SOP also apply when amendments are made to studies hosted by MEHT."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 25,
            "data": {
                "is_heading": 0,
                "prefix": 2.2,
                "text": "Amendments are changes to research studies after a REC favourable opinion has been granted and/or in the case of a Clinical Trial of an Investigational Medicinal Product (CTIMP), MHRA Clinical Trial Authorisation has been granted. They can be \u2018substantial' or \u2018non-substantial'."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 26,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "APPLICABLE TO"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 27,
            "data": {
                "is_heading": 0,
                "prefix": 3.1,
                "text": "Any Trust employee (including those with an honorary contract, letter of access or research passport) involved with clinical research sponsored by MEHT including, but not limited to; Chief Investigators (CI), Principal Investigators (PI), Consultants, Co-investigators, Clinical Trial Pharmacists, Research Managers, Statisticians, Research nurses, Research Midwives, Allied Health Professionals, Trial Coordinators, R&D Department & Data Managers."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 28,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "PROCEDURE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 29,
            "data": {
                "is_heading": 1,
                "prefix": 4.1,
                "text": "Sponsor Assessment of Amendments"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 30,
            "data": {
                "is_heading": 0,
                "text": "4.1.1  It is necessary to identify if an amendment is substantial or non-substantial. It is the responsibility of the Sponsor to determine whether an amendment is substantial or non-substantial, therefore you must liaise with the R&D Department when determining this classification for MEHT sponsored studies. R&D must also review the amendment prior to submission to HRA and REC and any implications it has for the management or delivery of the study."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 31,
            "data": {
                "is_heading": 1,
                "prefix": 4.2,
                "text": "Preparation and Submission of Amendments"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 32,
            "data": {
                "is_heading": 0,
                "text": "The HRA must be notified of both substantial and/or non-substantial amendments."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 33,
            "data": {
                "is_heading": 1,
                "text": "4.2.1 Substantial Amendments"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 34,
            "data": {
                "is_heading": 0,
                "text": "\u25cf If the amendment is deemed substantial a \u2018Notice of Substantial Amendment' (NOSA) form will need to be completed through the Integrated Research Application System (IRAS). It will be necessary to have all modified documents including tracked versions for upload along with any further supporting documentation required."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 35,
            "data": {
                "is_heading": 0,
                "text": "\u25cf For non-CTIMPs NOSA forms must be electronically authorised by both CI and Sponsor via IRAS"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 36,
            "data": {
                "is_heading": 0,
                "text": "\u25cf For CTIMPs, the EU NOSA forms must be electronically authorised by the Sponsor, CI, or another person authorised by the Sponsor, via IRAS"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 37,
            "data": {
                "is_heading": 0,
                "text": "\u25cf The method for submitting the amendment differs depending on the nature of the study:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 38,
            "data": {
                "is_heading": 0,
                "text": "\u25cb Where HRA approval for the study included NHS REC review, substantial amendments should then be submitted to REC via IRAS"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 39,
            "data": {
                "is_heading": 0,
                "text": "\u25cb Where the REC is in England, REC will notify HRA of the amendment, thus no separate submission to HRA is required. However, where the REC is in Scotland, Wales or Northern Ireland you should also copy in hra.amendments@nhs.net"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 40,
            "data": {
                "is_heading": 0,
                "text": "\u25cb Where the project did not require NHS REC review, the substantial amendment should be submitted directly to hra.amendments@nhs.net"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 41,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Substantial amendments for CTIMPs and/or Medical Devices with Clinical Trial Authorisation (CTA) will require MHRA review in addition to HRA and REC (although not all substantial amendments that require REC review also require MHRA review; you must consult R&D to determine whether MHRA need to be notified)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 42,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Substantial amendments will need to be submitted to MHRA using the European Commission form. This document is available from the EudraCT website or can be downloaded from the Amendment tab in IRAS. The form must be accompanied by an amended EudraCT application. Submission to MHRA is done outside of IRAS. Please liaise with R&D and refer to the MHRA website for the most up to date guidance  www.gov.uk/guidance/clinical-trials-for-medicines- manage-your-authorisation-report-safety-issues"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 43,
            "data": {
                "is_heading": 1,
                "text": "4.2.2 Non-Substantial Amendments"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 44,
            "data": {
                "is_heading": 0,
                "text": "\u25cf If the amendment is non-substantial a \u2018Notification of Non-Substantial/Minor Amendment' form should be completed by the CI. The template form can be found in resources on the HRA website: http://www.hra.nhs.uk/research- community/during-your-research-project/amendments/preparing-amendments/"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 45,
            "data": {
                "is_heading": 0,
                "text": "\u25cf The notification should be submitted, once approved by R&D, with any supporting documentation, by email to hra.amendments@nhs.net. Please include the IRAS ID for your project in the subject line of the email along with the text \u2018Notification of Amendment' and ensure that your email includes your contact"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 46,
            "data": {
                "is_heading": 0,
                "text": "details"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 47,
            "data": {
                "is_heading": 1,
                "prefix": 4.3,
                "text": "Categorisation of Amendments"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 48,
            "data": {
                "is_heading": 0,
                "text": "4.3.1 When amendments (both substantial and non-substantial) are submitted to REC/HRA, the HRA will categorise the amendment as either category A, B, or C within 5 business days."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 49,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Category A: Amendment that impacts or affects all participating NHS organisations."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 50,
            "data": {
                "is_heading": 0,
                "text": "All participating NHS organisations are expected to consider the amendment to"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 51,
            "data": {
                "is_heading": 0,
                "text": "determine whether they are able to continue to support the study."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 52,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Category B: Amendment that impacts or affects specific participating NHS organisations."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 53,
            "data": {
                "is_heading": 0,
                "text": "Only those participating NHS organisations affected by the amendment are"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 54,
            "data": {
                "is_heading": 0,
                "text": "expected to consider the amendment to determine whether they are able to continue to support the study."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 55,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Category C: Amendment that has no impact on NHS organisations"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 56,
            "data": {
                "is_heading": 0,
                "text": "Participating NHS organisations are NOT expected to consider the amendment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 57,
            "data": {
                "is_heading": 0,
                "text": "4.3.2 The applicant will be informed of this categorisation, and if there are participating NHS/Health and Social Care (HSC) sites in other nations, the HRA will share the amendment and categorisation with other participating nations."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 58,
            "data": {
                "is_heading": 0,
                "text": "4.3.3 It is the applicant's responsibility to communicate the categorisation and the amendment to English sites (i.e. the local research team, the R&D office and the LCRN, where appropriate - contact details for R&D offices and LCRNs are available via http://www.rdforum.nhs.uk/content/contact-details/"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 59,
            "data": {
                "is_heading": 0,
                "text": "4.3.4 The CI must send the amendment and the categorisation information to participating NHS organisations so that, where necessary, arrangements can be put in place to continue the site's capacity and capability to deliver the study. Instructions will be detailed further in the categorisation email from the HRA."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 60,
            "data": {
                "is_heading": 1,
                "prefix": 4.4,
                "text": "Implementation of Amendments"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 61,
            "data": {
                "is_heading": 0,
                "prefix": 35.0,
                "text": "4.4.1 There can be \u2018presumed implementation' following regulatory approval, unless an objection to the amendment is raised by an NHS organisation within a reasonable time. Presumed implementation of an amendment can occur after  days of notifying the site of that amendment (subject to other regulatory approvals being in place), unless the NHS organisation raised an objection within this period or requests additional review time."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 62,
            "data": {
                "is_heading": 0,
                "prefix": 35.0,
                "text": "4.4.2 Details will be outlined in the HRA categorisation letter as to which sites need to be given  days before presumed implementation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 63,
            "data": {
                "is_heading": 0,
                "text": "\u25cf For Category A and B amendments, NHS organisations have a maximum of 35 days to raise an objection; otherwise the amendment can be implemented after the 35 day period (Subject to regulatory approvals being in place)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 64,
            "data": {
                "is_heading": 0,
                "text": "\u25cf For Category C amendments can be implemented immediately (subject to regulatory approval being in place)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 65,
            "data": {
                "is_heading": 0,
                "text": "4.4.3 In all cases, the CI must ensure that amendments and any supporting documentation are sent to the local PIs and their research teams, and the local R&D office at all affected sites. Contact details for all R&D offices are available at http://www.rdforum.nhs.uk/content/contact-details/"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 66,
            "data": {
                "is_heading": 0,
                "text": "4.4.4 Where MEHT are a site, R&D will review all Category A and B amendments once the categorisation email is received, and aim to confirm continuing capacity and capability to host the study once it has been reviewed (or raise objection where necessary)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 67,
            "data": {
                "is_heading": 0,
                "prefix": 35.0,
                "text": "4.4.5 The confirmation of continuing capacity and capability email will confirm that the amendment is ready to be implemented at the site. The Sponsor or CI will then let the local site team know when they are ready for the amendment to be implemented (if not already made clear in the amendment submission). If no acknowledgment or request for additional review time is sent by R&D within  days of R&D being notified of the amendment and its categorisation, presumed implementation can occur."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 68,
            "data": {
                "is_heading": 1,
                "prefix": 4.5,
                "text": "Urgent Safety Measures (USM)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 69,
            "data": {
                "is_heading": 0,
                "text": "4.5.1 The Sponsor, CI or PI may take appropriate USMs in order to protect research participants against any immediate hazard to their health or safety. Approval is not required before taking these measures."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 70,
            "data": {
                "is_heading": 1,
                "text": "4.5.2 The REC, MHRA (in the case of the CTIMPs) and R&D office should be notified within 3 days of taking the measures, detailing the measures taken and the reasons why."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 71,
            "data": {
                "is_heading": 1,
                "text": "4.5.3 In the case of CTIMPs, the MHRA's Clinical Trial Unit should be phoned on 020 3080 6456 or emailed on clintrialhelpline@mhra.gov to discuss the issue with a safety scientist, ideally within 24 hours. This should then be submitted to the MHRA in writing within 3 days - MHRA will provide guidance for this submission. In cases where MEHT are sponsors, you must ensure you liaise with R&D throughout this process."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 72,
            "data": {
                "is_heading": 1,
                "text": "4.5.4 Where USMs are taken and the participant suffers harm, safety reporting procedures should be followed."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 73,
            "data": {
                "is_heading": 0,
                "text": "4.5.5 Where a USM represents a substantial amendment to the protocol or other documentation, a substantial amendment will need to be prepared and submitted following procedures outlined in this SOP."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 74,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "RELATED DOCUMENTS"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 75,
            "data": {
                "is_heading": 0,
                "text": "Health Research Authority - Process for handling UK study amendments www.hra.nhs.uk/documents/2014/11/guide-researchers-uk-process-handling-uk- study-amendments"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 76,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "EQUALITY IMPACT ASSESSMENT"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 77,
            "data": {
                "is_heading": 0,
                "prefix": 6.1,
                "text": "Mid Essex Hospital Services NHS Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals. (Refer to Appendix 6)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 78,
            "data": {
                "is_heading": 1,
                "text": "Appendix 1: Definitions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 79,
            "data": {
                "is_heading": 1,
                "text": "Chief Investigator"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 80,
            "data": {
                "is_heading": 0,
                "text": "A Registered Physician, Dentist, Pharmacist or Registered Nurse who has overall responsibility for the conduct of the trial."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 81,
            "data": {
                "is_heading": 1,
                "text": "Clinical Trial - Any investigation in human subjects, other than a non-interventional trial intended to discover or verify the clinical, pharmacological or other pharmacodynamic effects of one or more medicinal product or to identify any adverse reactions to one or more such products and to study absorption, distribution metabolism and excretion in one of more such products with the object of ascertaining the safety or efficacy of those products."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 82,
            "data": {
                "is_heading": 1,
                "text": "Clinical Trial Authorisation (CTA)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 83,
            "data": {
                "is_heading": 0,
                "text": "Regulatory approval issued by a Competent Authority to conduct a clinical trial within a Member State."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 84,
            "data": {
                "is_heading": 1,
                "text": "Clinical Trial of an Investigational Medicinal Product (CTIMP) - This is defined as any Clinical Research Study which intends to generate new information about the safety or efficacy of a Medicinal Product."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 85,
            "data": {
                "is_heading": 1,
                "text": "Investigational Medicinal Product (IMP)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 86,
            "data": {
                "is_heading": 0,
                "text": "A pharmaceutical form of an active substance or placebo being tested, or used as a reference in a clinical trial. This includes a medicinal product which has a marketing authorisation but is, for the purpose of the trial -"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 87,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Used or assembled (formulated or packaged) in a way different from the form of the product authorised under the authorisation,"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 88,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Used for an indication not included in the summary of product characteristics under the authorisation for that product,"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 89,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Used to gain further information about the form of that product as authorised under the authorisation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 90,
            "data": {
                "is_heading": 1,
                "text": "Non-Substantial Amendment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 91,
            "data": {
                "is_heading": 0,
                "text": "Minor changes to the original REC application, to the protocol, or any other supporting documentation that will NOT affect to a significant degree;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 92,
            "data": {
                "is_heading": 0,
                "text": "\u25cf The safety or physical or mental integrity of the subjects of the study;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 93,
            "data": {
                "is_heading": 0,
                "text": "\u25cf The scientific value of the study;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 94,
            "data": {
                "is_heading": 0,
                "text": "\u25cf The conduct or management of the study."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 95,
            "data": {
                "is_heading": 0,
                "text": "\u25cf The quality or safety of any investigational medicinal product used in the trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 96,
            "data": {
                "is_heading": 1,
                "text": "Principal Investigator (PI)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 97,
            "data": {
                "is_heading": 0,
                "text": "A Registered Physician, Dentist, Pharmacist or Registered Nurse who has responsibility for the conduct of the trial at a host site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 98,
            "data": {
                "is_heading": 1,
                "text": "Substantial Amendment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 99,
            "data": {
                "is_heading": 0,
                "text": "Amendments to the original REC application, to the protocol, or any other supporting documentation that is likely to affect to a significant degree:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 100,
            "data": {
                "is_heading": 0,
                "text": "\u25cf The safety or physical or mental integrity of the subjects of the study;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 101,
            "data": {
                "is_heading": 0,
                "text": "\u25cf The scientific value of the study;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 102,
            "data": {
                "is_heading": 0,
                "text": "\u25cf The conduct or management of the study;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 103,
            "data": {
                "is_heading": 0,
                "text": "\u25cf The quality or safety of any investigational medicinal product used in the trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 104,
            "data": {
                "is_heading": 1,
                "text": "The Medicines & Healthcare products Regulatory Agency (MHRA)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 105,
            "data": {
                "is_heading": 0,
                "text": "UK Competent Authority responsible for regulation of clinical trials."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 106,
            "data": {
                "is_heading": 1,
                "text": "Appendix 2: Flowchart of Amendment Process for Trusts Sponsored Studies"
            }
        },
        {
            "type": "image",
            "sequence_num": 107,
            "data": {
                "url": "MEHTSOP059 Amendments 1.0.002.jpeg"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 108,
            "data": {
                "is_heading": 1,
                "text": "Appendix 3: Examples of Substantial and Non-Substantial Amendments"
            }
        },
        {
            "type": "table",
            "sequence_num": 109,
            "data": {
                "num_rows": 3,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Term"
                    },
                    {
                        "text": "Examples (as defined by HRA)"
                    },
                    {
                        "text": "Substantial Amendment"
                    },
                    {
                        "text": "Changes to the design or methodology of the study, or to background information affecting its scientific value. Changes to the procedures undertaken by participants Any change relating to study documentation such as participant information sheets, consent forms, questionnaires, letters of invitation, letters to GPs or other clinicians, information sheets for relatives or carers. A change of Sponsor(s) or Sponsor's legal representative. Appointment of a new CI or key collaborator. A change to the insurance or indemnity arrangements for the study. Inclusion of a new trial site (not listed in the original application) in a CTIMP. Appointment of a new PI at a trial site in a CTIMP. Temporary halt of a study to protect participants from harm, and the planned restart of the study following a temporary halt. A change to the definition of the end of study. Any other significant change to the protocol or the terms of the REC application."
                    },
                    {
                        "text": "Non-Substantial Amendment"
                    },
                    {
                        "text": "Minor changes to the protocol or other study documentation, e.g. correcting errors, updating contact points, minor clarifications, updates of the investigator's brochure (unless there is a change to the risk/benefit assessment for the trial). Changes to the CI's research team (other than appointment of key collaborators). Changes to the research team at particular trial sites (other than appointment of a new PI in a CTIMP). Changes in funding arrangements."
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 110,
            "data": {
                "num_rows": 1,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": ""
                    },
                    {
                        "text": "Changes in the documentation used by the research team for recording study data. Changes in the logistical arrangements for storing or transporting samples. Inclusion of new sites and investigators in studies other than CTIMPs. Extension of the study beyond the period specified in the application form."
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 111,
            "data": {
                "is_heading": 0,
                "text": "Research & Development Amendments/ MEHTSOP059/1.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 112,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 113,
            "data": {
                "is_heading": 1,
                "text": "Appendix 4: Preliminary Equality Analysis"
            }
        },
        {
            "type": "image",
            "sequence_num": 114,
            "data": {
                "url": "MEHTSOP059 Amendments 1.0.003.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 115,
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to: Research & Development Amendments/ MEHTSOP059"
            }
        },
        {
            "type": "table",
            "sequence_num": 116,
            "data": {
                "num_rows": 9,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "A change in a service to patients"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to an existing policy"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to the way staff work"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A new policy"
                    },
                    {
                        "text": "X"
                    },
                    {
                        "text": "Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "New SOP"
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "Review"
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "Patients and clinicians"
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No"
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change? b) If so, with whom?"
                    },
                    {
                        "text": "Refer to pages 1 and 2"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 117,
            "data": {
                "is_heading": 1,
                "text": "Preliminary analysis completed by:"
            }
        },
        {
            "type": "table",
            "sequence_num": 118,
            "data": {
                "num_rows": 1,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Lauren Perkins"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Research & Development Manager"
                    },
                    {
                        "text": "Date"
                    },
                    {
                        "text": "July 2019"
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 119,
            "data": {
                "url": "MEHTSOP059 Amendments 1.0.001.png"
            }
        }
    ]
}